<DOC>
	<DOCNO>NCT00921024</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intravenous CXA 101 comparator complicate urinary tract infection</brief_summary>
	<brief_title>Safety Efficacy IV CXA-101 IV Ceftazidime Patients With Complicated Urinary Tract Infections</brief_title>
	<detailed_description>This Phase 2 , multicenter , prospective , randomize , double-blind , comparative efficacy safety study IV CXA 101 versus IV ceftazidime 7 10 day . Subjects follow 6 9 day last dose study drug assess clinical sign symptom infection . A Late Follow Up evaluation ( 21 28 day last dose study drug ) occur subject respond therapy . The primary assessment effectiveness microbiological response ( eradication post-therapy infectious organism identify start study ) . An additional assessment efficacy include overall clinical response , describe cure , improve , fail . Safety assessment include incidence adverse event throughout study , clinical laboratory test ( hematology , serum chemistry , urinalysis ) physical examination start study post-therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>1 . Males females 18 90 year age , inclusive . 2 . Pyuria ( white blood cell [ WBC ] count &gt; 10/µL unspun urine ≥ 10 per high power field spun urine ) 3 . Clinical sign and/or symptom cUTI , either : a. Pyelonephritis , indicate following : . Fever ( oral temperature ≥ 37.8°C ) ; ii . Flank pain costovertebral angle tenderness ; OR b . Complicated low UTI , indicate following : . At least one follow new worsen symptom : Dysuria ; Frequency ; Suprapubic pain ; Urgency ii . At least one follow complicate factor : Male gender ; Current bladder instrumentation indwell urinary catheter expect remove course IV study drug administration ; Obstructive uropathy expect medically surgically treated course IV study drug administration ; Urogenital surgery within 7 day precede administration first dose study drug ; Functional anatomical abnormality urogenital tract include anatomic malformation neurogenic bladder void disturbance least 100 mL residual urine . Exclusion Criteria 1 . Documented history hypersensitivity allergic reaction βlactam antibacterial 2 . Concomitant infection require systemic antibacterial therapy addition IV study drug therapy time randomization . Drugs grampositive activity ( e.g . vancomycin , linezolid ) allow 3 . Complete , permanent obstruction urinary tract 4 . Confirmed ( time randomization ) fungal urinary tract infection ( ≥ 103 fungal CFU/mL ) 5 . Suspected confirm perinephric intrarenal abscess 6 . Suspected confirm prostatitis 7 . Known ileal loop vesicoureteral reflux 8 . Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Complicated Urinary Tract Infection</keyword>
	<keyword>Pyelonephritis</keyword>
	<keyword>Antimicrobial</keyword>
	<keyword>Cephalosporin</keyword>
	<keyword>Intravenous</keyword>
</DOC>